| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2004 , Vol 46 , Num 1
IN VITRO STUDY OF ANTIBACTERIAL ACTIVITY OF CEFEPIME AND CEFPIROME AGAINST GRAM-NEGATIVE CLINICAL ISOLATES, COMPARED WITH THOSE OF NINE BROAD-SPECTRUM AGENTS
Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Teclmology, lrbid , Jordan
Viewed :
17175
-
Downloaded :
4542
The in vitro activities of cefepime and cefpirome were compared with those of cefoperazolle, ceftaziclime, ceftriaxone, ciprofloxacin, aztreonam, gentamicin, pipercillill, tobramycill, and ticarcillinlclavulanic. 302 clinical isolates, representing a cross-section of Klebsiella and Enterobacter species and Pseudomonas aeruginosa were tested. Cefepime and cefpirome demonstrated excellent ,activity against the majority of strains in all three genera of bacteria tested, as did ciprofloxacin and tobramycill. Ceftazidime was active against Pseudomonas aeruginosa but was less potent against Klebsiella and Enterobacter species. Cefoperazone, and ceftriaxone were less active than ceftazidime against Pseudomonas aeruginosa.
Keywords :
CEFEPIME, CEFPIROME, ANTIBAC,TERIAL ACTIVITY, CROSHESISTANCE